CG Oncology (CGON) to Release Earnings on Friday

Key Points

• CG Oncology is expected to release its Q2 2025 earnings on Thursday, August 14th, with analysts predicting a loss of ($0.49) per share and revenue of $0.11 million.
• The company's last earnings report indicated a loss of ($0.45) EPS, significantly below analyst estimates, and marked a negative return on equity of 16.71%.
• Institutional investors have shown increased interest, with UBS AM raising its stake by 42.5%, while the average analyst rating for CG Oncology stocks remains a "Buy" with a consensus price target of $55.30.

CG Oncology (NASDAQ:CGON - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Friday, August 8th. Analysts expect the company to announce earnings of ($0.49) per share and revenue of $0.11 million for the quarter.

CG Oncology (NASDAQ:CGON - Get Free Report) last issued its earnings results on Friday, August 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.05). CG Oncology had a negative return on equity of 16.71% and a negative net margin of 15,945.17%. On average, analysts expect CG Oncology to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CG Oncology Stock Up 2.1%

Shares of CGON traded up $0.50 during midday trading on Friday, reaching $24.85. The company had a trading volume of 669,886 shares, compared to its average volume of 999,596. CG Oncology has a 1-year low of $14.80 and a 1-year high of $40.47. The stock has a market cap of $1.89 billion, a PE ratio of -14.04 and a beta of 0.87. The firm has a 50 day simple moving average of $26.29 and a 200-day simple moving average of $25.65.

Insider Buying and Selling at CG Oncology

In related news, Director Leonard E. Post sold 2,000 shares of the business's stock in a transaction on Thursday, July 17th. The stock was sold at an average price of $28.00, for a total transaction of $56,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 7.40% of the company's stock.

Hedge Funds Weigh In On CG Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in CGON. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in CG Oncology by 42.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 179,363 shares of the company's stock worth $4,393,000 after acquiring an additional 53,461 shares during the last quarter. Millennium Management LLC lifted its stake in CG Oncology by 139.4% in the first quarter. Millennium Management LLC now owns 596,056 shares of the company's stock worth $14,597,000 after acquiring an additional 347,055 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in CG Oncology by 18.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,522 shares of the company's stock worth $876,000 after acquiring an additional 5,442 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new position in CG Oncology in the first quarter worth approximately $475,000. 26.56% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently issued reports on CGON shares. Morgan Stanley boosted their price objective on shares of CG Oncology from $52.00 to $56.00 and gave the company an "overweight" rating in a report on Tuesday, June 17th. The Goldman Sachs Group raised shares of CG Oncology to a "strong-buy" rating and set a $40.00 price target on the stock in a research note on Thursday, July 10th. Wall Street Zen cut shares of CG Oncology from a "hold" rating to a "sell" rating in a research report on Saturday. Cantor Fitzgerald reiterated an "overweight" rating and issued a $75.00 target price on shares of CG Oncology in a report on Monday, April 28th. Finally, Royal Bank Of Canada decreased their price target on CG Oncology from $68.00 to $53.00 and set an "outperform" rating on the stock in a research note on Wednesday, July 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $55.30.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.